Xagrid (anagrelide hydrochloride): Risk of thrombosis including cerebral infarction upon abrupt treatment discontinuation

Table of contents

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Key facts

Medicine name
Xagrid
Active substance
Anagrelide
Therapeutic area (MeSH)
Thrombocythemia, Essential
Procedure number
EMEA/H/C/000480/II/091
Regulatory outcome
Variation
DHPC type
Safety signal
Human ATC code
L01XX35
Dissemination date
22/02/2022

How useful was this page?

Add your rating